Keywords
Precision medicine
Genomics
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: Analyze the biomedical, socioeconomic and ethical impacts of personalized medicine. Literature review: Personalized medicine achieves concrete advances in genomics and molecular biology, based on the premise that each individual is a unique and singular genetic organism. In this way, precision medicine allows for greater accuracy in early diagnosis, prevention and specific treatment of the health service user, especially in congenital metabolic disorders, such as cystic fibrosis. These advances in this technology make it the target of several global investments and financing, but reveal several obstacles and challenges to the full consolidation of this health mechanism, as it involves ethical implications for the privacy of genetic data and financial implications for democratization and popularization of equity in access. to this technological tool. Final considerations: Precision medicine is a promising healthcare strategy in the development of medical practice. Personalized medicine is capable of deepening inequality in access to health services and breaking the ethical confidentiality of patient genetic information.
References
AU L DA SILVA RGL. Globalizing the Scientific Bandwagon: Trajectories of Precision Medicine in China and Brazil. Science, Technology, & Human Values, 2021; 46(1): 192-225.
BARKER RW. Is precision medicine the future of healthcare? Per Med, 2017; 14(6): 459-461.
BAYER R e GALEA S. Public health in the precision-medicine era. N Engl J Med, 2015; 373: 499-501.
CLARKE AE, et al. Biomedicalization: technoscience, health, and illness in the U.S. Durham: Duke University Press. American Sociological Review, 2003; 68: 161-94.
COLLINS FS e VARMUS H. A new initiative on precision medicine. N Engl J Med, 2015; 372: 793-5.
COOTE JH e JOYNER MJ. Is precision medicine the route to a healthy world? Lancet, 2015; 385(9978): 1617.
DA SILVA R. Uma reflexão sobre agendas de pesquisa e inovação em saúde na pandemia da COVID-19. Jour 2020; 14: 1-8.
FOUNDATION ES. Personalised Medicine for the European citizen - towards more precise medicine for the diagnosis, treatment and prevention of disease. Strasbourg, 2012. Disponível em: . Acesso em: 12 fev. 2024.
HOOD L e FRIEND SH. Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat Rev Clin Oncol, 2011; 8(3): 184-7.
IRIART JAB. Medicina de precisão/medicina personalizada: análise crítica dos movimentos de transformação da biomedicina no início do século XXI. Cad Saúde Pública [Internet]. 2019; 35(3): 00153118.
JASANOFF S. States of knowledge: the co-production of science and the social order. London: Routledge; 2004. Disponível em: https ://www.routledge.com. Acesso em: 11 fev. 2024.
JOHNSON KB, et al. Precision Medicine, AI, and the Future of Personalized Health Care. Clin Transl Sci. 2021; 14(1): 86-93.
JOYNER MJ e PANETH N. Seven Questions for Personalized Medicine. Jama, 2015; 314(10): 999-1000.
KHOURY MJ, et al. Precision Public Health for the Era of Precision Medicine. Am J Prev Med, 2016. 50(3): 398-401.
KHOURY MJ e GALEA S. Will precision medicine improve population health? JAMA, 2016; 316(13): 1357-8.
MAMOSHINA P, et al. Converging blockchain and next-generation artificial intelligence technologies to decentralize and accelerate biomedical research and healthcare. Oncotarget, 2017; 9(5): 5665-90.
MARCUS AD. Covid-19 Raises Questions About the Value of Personalized Medicine. 2020. Disponível em: https ://www.wsj.com/articles/covid-19-raises-questions-about-the-value-of-personalized-medicine-11588949927. Acesso em: 11 fev. 2024.
MAUGHAN T. The Promise and the Hype of 'Personalised Medicine'. New Bioeth, 2017; 23(1), 13-20.
MITTELSTADT BD, FLORIDI L. The Ethics of Big Data: Current and Foreseeable Issues in Biomedical Contexts. Sci Eng Ethics, 2016; 22(2): 303-41.
PARENS E. The Inflated Promise of Genomic Medicine: COVID-19 has laid bare the need to reconsider the hope and money we invest in genetics research. Scientific American, 2020. Disponível em: https ://www.geneticsandsociety.org/article/inflated-promise-genomic-medicine. Acesso em: 15 fev. 2024.
PEREZ B. China's 'precision medicine' initiative gets lift from latest genomics company funding. South China Morning Post 2017. Disponívem em: https ://www.scmp.com/tech/china-tech/article/2092362/chinas-precision-medicine-initiative-gets-lift-latest-genomics. Acesso em: 15 fev. 2024.
PHILLIPS KA, et al. Genetic Test Availability And Spending: Where Are We Now? Where Are We Going? Health Aff (Millwood), 2018; 37(5): 710-716.
RICHARD COOPER NP. Precision medicine: course correction urgently needed. 2020. Disponível em: < https ://www.statnews.com/2020/03/03/precision-medicine-course-correction-urgently-needed/ >. Acesso em: 16 fev. 2024.
ROSE N. A biomedicina transformará a sociedade? O impacto político, econômico, social e pessoal dos avanços médicos no século XXI. Psicol Soc, 2010; 22(3): 628-38.
TEIXEIRA TWD, et al. Medicina personalizada no tratamento do câncer/Personalized medicine in cancer treatment. Brazilian Journal of Health Review, 2020; 3(6): 18789-18793.
TOLEDO K. Primeiro banco público de dados genômicos da América Latina é lançado. 2015. Disponível em :https ://agencia.fapesp.br/primeiro-bancopublicodedadosgenomicosdaamericalatinaelancado/22255. Acesso em: 11 fev. 2024.
TOPOL EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med, 2019; 25(1): 44-56.